Alzheimer’s biotech vTv Therapeutics files for a $173 million IPO

vTv Therapeutics, a biotech developing treatments for Alzheimer’s and type 2 diabetes, filed on Monday with the SEC to raise up to $173 million in an initial public offering.

The High Point, NC-based company, which was founded in 1998 and booked $2 million in sales for the 12 months ended March 31, 2015, plans to list on the NASDAQ under the symbol VTVT. Piper Jaffray and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.